Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi

PLoS Neglected Tropical Diseases

Volumn 8, Issue 7, 2014, Pages

  Planer, Joseph D ^a   Hulverson, Matthew A ^a   Arif, Jennifer A ^a   Ranade, Ranae M ^a   Don, Robert ^b   Buckner, Frederick S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; BENZNIDAZOLE; CHLORPROTHIXENE; CLEMASTINE; FLUOXETINE; MEFLOQUINE; MINOCYCLINE; PAROXETINE; POSACONAZOLE; PRIMAQUINE; PYRIMETHAMINE; SERTRALINE; SIMVASTATIN; THIORIDAZINE; TRIAMTERENE; ANTITRYPANOSOMAL AGENT; DRUG COMBINATION; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG SCREENING; FEMALE; FIBROBLAST; FOOD AND DRUG ADMINISTRATION; GROWTH INHIBITION; MORTALITY; MOUSE; NONHUMAN; PARASITEMIA; SURVIVAL; TRYPANOSOMA CRUZI; ANIMAL; BAGG ALBINO MOUSE; DRUG COMBINATION; DRUG EFFECTS;

ANIMALS; CLEMASTINE; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; MICE; MICE, INBRED BALB C; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84905487382     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002977     Document Type: Article

References (55)

1. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ, (2013) Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 13: 342-348 S1473-3099(13)70002-1 [pii];10.1016/S1473-3099(13)70002-1 [doi].
2. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 3: e484.
3. Coura JR, Vinas PA, (2010) Chagas disease: a new worldwide challenge. Nature 465: S6-S7.
4. Andriani G, Chessler AD, Courtemanche G, Burleigh BA, Rodriguez A, (2011) Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis 5: e1298 10.1371/journal.pntd.0001298 [doi];PNTD-D-11-00561 [pii].
5. Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, et al. (2010) Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob Agents Chemother 54: 3326-3334.
6. Sykes ML, Avery VM, (2013) Approaches to Protozoan Drug Discovery: Phenotypic Screening. J Med Chem 10.1021/jm4004279 [doi].
7. Apt W, Arribada A, Zulantay I, Solari A, Sanchez G, et al. (2005) Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 99: 733-741.
8. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, et al. (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77: 10288-10294.
9. Buckner FS, Bahia MT, Suryadevara PK, White KL, Shackleford DM, et al. (2012) Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother 56: 4914-4921 AAC.06244-11 [pii];10.1128/AAC.06244-11 [doi].
10. Buckner FS, Griffin JH, Wilson AJ, Van Voorhis WC, (2001) Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother 45: 1210-1215.
11. Buckner FS, Verlinde CLMJ, La Flamme AC, Van Voorhis WC, (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob Agents Chemother 40: 2592-2597.
12. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
13. Fivelman QL, Adagu IS, Warhurst DC, (2004) Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48: 4097-4102 48/11/4097 [pii];10.1128/AAC.48.11.4097-4102.2004 [doi].
14. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, et al. (2009) Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 52: 1639-1647.
15. Lo Presti MS, Rivarola HW, Bustamante JM, Fernandez AR, Enders JE, et al. (2004) Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice. Int J Antimicrob Agents 23: 634-636 10.1016/j.ijantimicag.2003.10.006 [doi];S0924857904000652 [pii].
16. Rivarola HW, Paglini-Oliva PA, (2002) Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr Drug Targets Cardiovasc Haematol Disord 2: 43-52.
17. Loiseau PM, Mettey Y, Vierfond JM, (1996) Antifilarial and trypanocidal properties of phenothiazines and related polycyclics as new lead structures. Int J Parasitol 26: 1115-1117 S0020-7519(96)80011-7 [pii].
18. Page AM, Lagnado JR, (1995) Effects of phenothiazine neuroleptic drugs on the microtubular-membrane complex in bloodstream forms of Trypanosoma brucei. Parasitology 111 (Pt 4):: 493-504.
19. Rice H, Ruben L, Gould S, Njogu AR, Patton CL, (1987) Phenothiazines in murine African trypanosomiasis. Trans R Soc Trop Med Hyg 81: 932.
20. Seebeck T, Gehr P, (1983) Trypanocidal action of neuroleptic phenothiazines in Trypanosoma brucei. Mol Biochem Parasitol 9: 197-208 0166-6851(83)90097-X [pii].
21. Rivarola HW, Fernandez AR, Enders JE, Fretes R, Gea S, et al. (1999) Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice. Ann Trop Med Parasitol 93: 695-702.
22. Chan C, Yin H, Garforth J, McKie JH, Jaouhari R, et al. (1998) Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem 41: 148-156 10.1021/jm960814j [doi];jm960814j [pii].
23. de Castro SL, Soeiro MN, De Meirelles MN, (1992) Trypanosoma cruzi: effect of phenothiazines on the parasite and its interaction with host cells. Mem Inst Oswaldo Cruz 87: 209-215 S0074-02761992000200007 [pii].
24. Doyle PS, Weinbach EC, (1989) The activity of tricyclic antidepressant drugs against Trypanosoma cruzi. Exp Parasitol 68: 230-234 0014-4894(89)90102-1 [pii].
25. Fauro R, Lo PS, Bazan C, Baez A, Strauss M, et al. (2013) Use of clomipramine as chemotherapy of the chronic phase of Chagas disease. Parasitology 140: 917-927 S0031182013000103 [pii];10.1017/S0031182013000103 [doi].
26. Bazan PC, Lo Presti MS, Rivarola HW, Triquell MF, Fretes R, et al. (2008) Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment. Parasitol Res 103: 663-669 10.1007/s00436-008-1029-x [doi].
27. Rivarola HW, Fernandez AR, Enders JE, Fretes R, Gea S, et al. (2001) Effects of clomipramine on Trypanosoma cruzi infection in mice. Trans R Soc Trop Med Hyg 95: 529-533.
28. Garforth J, Yin H, McKie JH, Douglas KT, Fairlamb AH, (1997) Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine. J Enzyme Inhib 12: 161-173.
29. Reimao JQ, Scotti MT, Tempone AG, (2010) Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study. Bioorg Med Chem 18: 8044-8053 S0968-0896(10)00830-8 [pii];10.1016/j.bmc.2010.09.015 [doi].
30. Benaim G, Sanders JM, Garcia-Marchan Y, Colina C, Lira R, et al. (2006) Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 49: 892-899.
31. Veiga-Santos P, Barrias ES, Santos JF, de Barros Moreira TL, et al. (2012) Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 40: 61-71 S0924-8579(12)00126-4 [pii];10.1016/j.ijantimicag.2012.03.009 [doi].
32. Beach DH, Goad LJ, Holz GG Jr, (1986) Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochem Biophys Res Commun 136: 851-856.
33. Horvath AE, Zierdt CH, (1974) The effect of amphotericin B on Trypanosoma cruzi in vitro and in vivo. J Trop Med Hyg 77: 144-149.
34. Yardley V, Croft SL, (1999) In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg 61: 193-197.
35. Clayton J, (2010) Chagas disease: pushing through the pipeline. Nature pp. S12-S15.
36. Otigbuo IN, Onabanjo AO, (1992) The in vitro and in vivo effects of mefloquine on Trypanosoma brucei brucei. J Hyg Epidemiol Microbiol Immunol 36: 191-199.
37. Yardley V, Gamarro F, Croft SL, (2010) Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine. Antimicrob Agents Chemother 54: 5356-5358 AAC.00985-10 [pii];10.1128/AAC.00985-10 [doi].
38. Tekwani BL, Walker LA, (2006) 8-Aminoquinolines: future role as antiprotozoal drugs. Curr Opin Infect Dis 19: 623-631 10.1097/QCO.0b013e328010b848 [doi];00001432-200612000-00015 [pii].
39. Chung MC, Goncalves MF, Colli W, Ferreira EI, Miranda MT, (1997) Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine. J Pharm Sci 86: 1127-1131 10.1021/js970006v [doi];10.1021/js970006v [pii].
40. Kinnamon KE, Poon BT, Hanson WL, Waits VB, (1996) Primaquine analogues that are potent anti-Trypanosoma cruzi agents in a mouse model. Ann Trop Med Parasitol 90: 467-474.
41. McCabe RE, (1988) Primaquine is lethal for intracellular but not extracellular Trypanosoma cruzi. J Parasitol 74: 748-753.
42. Beveridge E, Caldwell IC, Latter VS, Neal RA, Udall V, et al. (1980) The activity against Trypanosoma cruzi and cutaneous leishmaniasis, and toxicity, of moxipraquine (349C59). Trans R Soc Trop Med Hyg 74: 43-51.
43. Mishina YV, Krishna S, Haynes RK, Meade JC, (2007) Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth. Antimicrob Agents Chemother 51: 1852-1854 AAC.01544-06 [pii];10.1128/AAC.01544-06 [doi].
44. Sienkiewicz N, Jaroslawski S, Wyllie S, Fairlamb AH, (2008) Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol 69: 520-533 MMI6305 [pii];10.1111/j.1365-2958.2008.06305.x [doi].
45. Corcino J, Waxman S, Herbert V, (1970) Mechanism of triamterene-induced megaloblastosis. Ann Intern Med 73: 419-424.
46. Masocha W, Rottenberg ME, Kristensson K, (2006) Minocycline impedes African trypanosome invasion of the brain in a murine model. Antimicrob Agents Chemother 50: 1798-1804 50/5/1798 [pii];10.1128/AAC.50.5.1798-1804.2006 [doi].
47. Amin DN, Masocha W, Ngan'dwe K, Rottenberg M, Kristensson K, (2008) Suramin and minocycline treatment of experimental African trypanososmiasis at an early stage of parasite brain invasion. Acta Trop 106: 72-74 S0001-706X(08)00026-0 [pii];10.1016/j.actatropica.2008.01.005 [doi].
48. Connell SR, Tracz DM, Nierhaus KH, Taylor DE, (2003) Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47: 3675-3681.
49. Urbina JA, (2009) Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104 (Suppl 1):: 311-318.
50. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, et al. (2001) Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 276: 33930-33937.
51. Lazardi K, Urbina JA, de Souza W, (1990) Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 34: 2097-2105.
52. Morand OH, Aebi JD, Dehmlow H, Ji YH, Gains N, et al. (1997) Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res 38: 373-390.
53. Thuita JK, Wang MZ, Kagira JM, Denton CL, Paine MF, et al. (2012) Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. PLoS Negl Trop Dis 6: e1734 10.1371/journal.pntd.0001734 [doi];PNTD-D-12-00125 [pii].
54. Diniz LF, Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, et al. (2013) Benznidazole and posaconazole in experimental chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 7: e2367 10.1371/journal.pntd.0002367 [doi];PNTD-D-13-00222 [pii].
55. Shah BM, Schafer JJ, Priano J, Squires KE, (2013) Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection. Pharmacotherapy 10.1002/phar.1237 [doi].